SCHEMBL13610474

SCHEMBL13610474

c1ccc(CSSSCc2nc3ccccc3s2)nc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.60
NPC1 O15118 7/20 0.60
SMN1; SMN2 Q16637 10/20 0.49
KMT2A Q03164 3/20 0.47
HPGD P15428 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 2/20 0.47
UBE2T Q9NPD8 1/20 0.46
ASIC3 Q9UHC3 1/20 0.46
MAPT P10636 3/20 0.45
TSHR P16473 2/20 0.45
PDE10A Q9Y233 1/20 0.45
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 1/20 0.42
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13610500 0.85 RAB9A (0.50) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL13610529 0.84 RAB9A (0.48) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL7595078 0.82 NPC1 (0.61) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL13610521 0.82 RAB9A (0.58) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL13610516 0.76 SMN1; SMN2 (0.51) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL13610522 0.76 PDK1 (0.57) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL10867611 0.75 RAB9A (0.62) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL13780226 0.75 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2HPGDALDH1A1
SCHEMBL13610356 0.75 SMN1; SMN2 (0.53) RAB9ANPC1SMN1; SMN2KMT2AHPGD
SCHEMBL13610514 0.75 RAB9A (0.62) RAB9ANPC1SMN1; SMN2KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742635-B1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES INC (US) 2018-03-07 EP disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF TST, CTH, CBS RAB9A 4609/4885NPC1 3127/4885SMN1; SMN2 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.